Infectious Disease Clinical Trials Market Expected To Grow At 7.1% CAGR Through 2030: What Businesses Need To Know

Infectious Disease Clinical Trials Market Report

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Infectious Disease Clinical Trials Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The infectious disease clinical trials market size has shown strong growth in recent years. This market is expected to increase from $15.1 billion in 2025 to $16.13 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. The historical growth in this sector is due to factors such as the expansion of the global infectious disease burden, increased funding for vaccine development, the growth in multinational clinical trial networks, the adoption of digital trial management systems, and rising public health research initiatives.

The market for infectious disease clinical trials is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $21.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. Factors driving this growth during the projected timeframe include heightened investments in pandemic preparedness, the growing application of AI-assisted patient recruitment, the widening scope of global trial decentralization, an intensifying emphasis on accelerated regulatory approvals, and the greater incorporation of digital biomarkers. Key trends anticipated during the forecast period involve the expanding embrace of data-driven trial design, the increasing implementation of decentralized clinical trial models, the deepening integration of real-world evidence, the broader deployment of adaptive trial methodologies, and a stronger focus on rapid pathogen response.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=29097&type=smp&name=Infectious%20Disease%20Clinical%20Trials%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Infectious Disease Clinical Trials Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The expansion of healthcare infrastructure is anticipated to drive the future growth of the infectious disease clinical trials market. This infrastructure encompasses physical facilities, medical equipment, technologies, and a skilled workforce that underpin the provision of healthcare services and enable effective prevention, diagnosis, and treatment of diseases. The development of healthcare infrastructure is increasing due to the rising demand for sophisticated medical services, the escalating burden of novel and complex diseases, and the necessity for well-equipped facilities and proficient healthcare professionals to deliver timely diagnosis, treatment, and preventative care. Healthcare infrastructure directly supports the capacity for clinical trials by offering advanced medical facilities, specialized equipment, and enhanced research capabilities crucial for conducting extensive studies on infectious diseases. For instance, in January 2025, the American Hospital Association, a US-based non-profit organization, projects that the total number of hospitals in the United States will reach 6,093 by 2025, indicating a moderate increase in healthcare facilities nationwide. Thus, the growing healthcare infrastructure is fueling the expansion of the infectious disease clinical trials market.

Infectious Disease Clinical Trials Market Segmentation And Category Overview

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

Infectious Disease Clinical Trials Market Innovation Trends Shaping Future Development

Companies operating within the infectious disease clinical trials market are increasingly focused on developing advanced research initiatives, such as Phase 3 trials for antibiotic candidates, to assist in identifying rare side effects and confirming optimal dosing. A Phase 3 trial for antibiotic candidates represents a late-stage investigation, testing the drug in a large cohort of patients to thoroughly evaluate its safety profile, effectiveness, and how it compares to existing treatments before it can receive approval for use. For instance, in May 2025, Roche, a pharmaceutical company based in Switzerland, initiated a Phase 3 clinical trial for zosurabalpin, an innovative tethered macrocyclic peptide antibiotic specifically designed to combat CRAB, a critical contributor to severe hospital infections worldwide. The unique characteristic of zosurabalpin lies in its novel mechanism of action, which obstructs the transport of lipopolysaccharide, a vital component for constructing the bacterial outer membrane, with no reported resistance thus far. This global trial is set to involve approximately 400 patients to assess its safety and effectiveness in comparison to standard treatments. Preliminary research has already indicated powerful activity against multidrug-resistant bacteria, excellent tolerability, and encouraging pharmacokinetic properties. This places Zosurabalpin as a potentially groundbreaking solution for tackling the urgent issue of antibiotic resistance.

Infectious Disease Clinical Trials Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

View The Full Infectious Disease Clinical Trials Market Report:

https://thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Infectious Disease Clinical Trials Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model